Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Vulvar Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

PD-L1 expression	Vulvar Cancer	PD-L1 expression	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
NTRK3 fusion	Vulvar Cancer	NTRK3 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Vulvar Cancer	NTRK2 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Vulvar Cancer	NTRK1 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Vulvar Cancer	NTRK3 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Vulvar Cancer	NTRK2 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Vulvar Cancer	NTRK1 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Vulvar Cancer	MSI-H/dMMR	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Vulvar Cancer	TMB-H	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2